Menu
  1. Dilley J, Gentry-Maharaj A, Ryan A, Burnell M, Manchanda R, Kalsi J, Singh N, Woolas R, Sharma A, Williamson K, Mould T, Fallowfield L, Campbell S, Skates SJ, McGuire A, Parmar M, Jacobs I, Menon U. Ovarian cancer symptoms in pre-clinical invasive epithelial ovarian cancer - An exploratory analysis nested within the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Gynecol Oncol. 2023 Nov 17;179:123-130. doi: 10.1016/j.ygyno.2023.11.005. Epub ahead of print. PMID: 37980767.
  2. Menon U, Gentry-Maharaj A, Burnell M, Apostolidou S, Ryan A, Kalsi JK, et al. Insights from UKCTOCS for design, conduct and analyses of large randomised controlled trials [published online ahead of print August 23 2023]. Health Technol Assess 2023. https://doi.org/10.3310/CLDC7214.
  3. Menon U, Gentry-Maharaj A, Burnell M, Ryan A, Singh N, Manchanda R, Kalsi JK, Woolas R, Arora R, Casey L, Dawnay A, Sharma A, Williamson K, Apostolidou S, Fallowfield L, McGuire AJ, Campbell S, Skates SJ, Jacobs IJ, Parmar MKB. Tumour stage, treatment, and survival of women with high-grade serous tubo-ovarian cancer in UKCTOCS: an exploratory analysis of a randomised controlled trial. Lancet Oncol. 2023 Sep;24(9):1018-1028. doi: 10.1016/S1470-2045(23)00335-2. PMID: 37657461.
  4. Menon U, Gentry-Maharaj A, Burnell M, Ryan A, Kalsi JK, Singh N, Dawnay A, Fallowfield L, McGuire AJ, Campbell S, Skates SJ, Parmar M, Jacobs IJ. Mortality impact, risks, and benefits of general population screening for ovarian cancer: the UKCTOCS randomised controlled trial. Health Technol Assess. 2023 May 11:1-81. doi: 10.3310/BHBR5832. Epub ahead of print. PMID: 37183782.
  5. Taylor JA, Burnell M, Ryan A, Karpinskyj C, Kalsi JK, Taylor H, Apostolidou S, Sharma A, Manchanda R, Woolas R, Campbell S, Parmar M, Singh N, Jacobs IJ, Menon U, Gentry-Maharaj A. Association of hysterectomy and invasive epithelial ovarian and tubal cancer: A cohort study within UKCTOCS. BJOG. 2021 Sep 23. doi: 10.1111/1471-0528.16943.
  6. Menon U, Gentry-Maharaj A, Burnell M, Singh N, Ryan A, Karpinskyj C, Carlino G, Taylor J, Massingham SK, Raikou M, Kalsi JK, Woolas R, Manchanda R, Arora R, Casey L, Dawnay A, Dobbs S, Leeson S, Mould T, Seif MW, Sharma A, Williamson K, Liu Y, Fallowfield L, McGuire AJ, Campbell S, Skates SJ, Jacobs IJ, Parmar M. Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. Lancet. 2021 Jun 5;397(10290):2182-2193. doi: 10.1016/S0140-6736(21)00731-5. Epub 2021 May 12. PMID: 33991479.
  7. Kalsi J, Gentry-Maharaj A, Ryan A, Singh N, Burnell M, Massingham S, Apostolidou S, Sharma A, Williamson K, Seif M, Mould T, Woolas R, Dobbs S, Leeson S, Fallowfield L, Skates SJ, Parmar M, Campbell S, Jacobs I, McGuire A, Menon U. Performance Characteristics of the Ultrasound Strategy during Incidence Screening in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Cancers (Basel). 2021 Feb 18;13(4):858. doi: 10.3390/cancers13040858. PMID: 33670571; PMCID: PMC7922843.
  8. Kalsi JK, Ryan A, Gentry-Maharaj A, Margolin-Crump D, Singh N, Burnell M, Benjamin E, Apostolidou S, Habib M, Massingham S, Karpinskyj C, Woolas R, Widschwendter M, Fallowfield L, Campbell S, Skates S, McGuire A, Parmar M, Jacobs I, Menon U. Completeness and accuracy of national cancer and death registration for outcome ascertainment in trials-an ovarian cancer exemplar. Trials. 2021 Jan 25;22(1):88. doi: 10.1186/s13063-020-04968-x. PMID: 33494753; PMCID: PMC7831170.
  9. Dilley J, Burnell M, Gentry-Maharaj A, Ryan A, …Menon U. Ovarian cancer symptoms, routes to diagnosis and survival – population cohort study in the ‘no screen’ arm of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Gynecologic Oncology 2020 June 17. DOI: 10.1016/j.ygyno.2020.05.002. PMID: 32561125.
  10. Karpinskyj C, Burnell M, Gonzalez-Izquierdo A, Ryan A, Kalsi J, Jacobs I, Parmar M, Menon U, Gentry-Maharaj A. Socioeconomic Status and Ovarian Cancer Stage at Diagnosis: A Study Nested Within UKCTOCS. Diagnostics (Basel). 2020 Feb 7;10(2):89. doi: 10.3390/diagnostics10020089. PMID: 32046189; PMCID: PMC7168054.
  11. Burnell M, Gentry-Maharaj A, Glazer C, Karpinskyj C, Ryan A, Apostolidou S, Kalsi J, Parmar M, Campbell S, Jacobs I, Menon U. Serial endometrial thickness and risk of non-endometrial hormone-dependent cancers in postmenopausal women in UK Collaborative Trial of Ovarian Cancer Screening. Ultrasound Obstet Gynecol. 2020 Aug;56(2):267-275. doi: 10.1002/uog.21894. PMID: 31614036; PMCID: PMC7496247.
  12. Harder H, Starkings RML, Fallowfield LJ, Menon U, Jacobs IJ, Jenkins VA; UKCTOCS trialists. Sexual functioning in 4,418 postmenopausal women participating in UKCTOCS: a qualitative free-text analysis. Menopause. 2019 Oct;26(10):1100-1009. doi: 10.1097/GME.0000000000001377. PMID: 31290761; PMCID: PMC6791508.
  13. Stott W, Gentry-Maharaj A, Ryan A, Amso N, Seif M, Jones C, Jacobs I, Parmar M, Menon U, Campbell S, Burnell M. Audit of transvaginal sonography of normal postmenopausal ovaries by sonographers from the United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). F1000Res. 2018 Aug 10;7:1241. doi: 10.12688/f1000research.15663.1. PMID: 30345030; PMCID: PMC6173132.
  14. Menon U, McGuire AJ, Raikou M, Ryan A, Davies SK, Burnell M, et al. The cost-effectiveness of screening for ovarian cancer: results from the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Br J Cancer. 2017;117(5):619-27.
  15. Stott W, Campbell S, Franchini A, Blyuss O, Zaikin A, Ryan A, Jones C, Gentry-Maharaj A, Fletcher G, Kalsi J, Skates S, Parmar M, Amso N, Jacobs I, Menon U. Self-reported transvaginal ultrasound visualization of normal ovaries in postmenopausal women is not reliable: results of expert review of archived images in UKCTOCS. Ultrasound Obstet Gynecol. 2017 Aug 10. doi: 10.1002/uog.18836. [Epub ahead of print] PubMed PMID: 28796383.
  16. Fallowfield L, Solis-Trapala I, Menon U, Langridge C, May S, Jacobs I, Jenkins V. The effect of ovarian cancer screening on sexual activity and functioning: results from the UK collaborative trial of ovarian cancer screening RCT. Br J Cancer. 2017 Apr 11;116(8):1111-1117. doi: 10.1038/bjc.2017.72. Epub 2017 Mar 21. PubMed PMID: 28324886; PubMed Central PMCID: PMC5396121.
  17. Jacobs IJ, Menon U, Ryan A, Gentry-Maharaj A, Burnell M, Kalsi JK, et al. Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. Lancet. 2016;387(10022):945-56
  18. Jenkins V, Fallowfield L, Langridge C, Barrett J, Ryan A, Jacobs I, Kilkerr J, Menon U, Farewell V. Psychosocial Factors Associated With Withdrawal From the United Kingdom Collaborative Trial of Ovarian Cancer Screening After 1 Episode of Repeat Screening. Int J Gynecol Cancer. 2015 Oct;25(8):1519-25. doi: 10.1097/IGC.0000000000000507. PubMed PMID: 26222482; PubMed Central PMCID: PMC4582418.
  19. Menon U, Ryan A, Kalsi J, Gentry-Maharaj A, Dawnay A, Habib M, Apostolidou S, Singh N, Benjamin E, Burnell M, Davies S, Sharma A, Gunu R, Godfrey K, Lopes A, Oram D, Herod J2, Williamson K, Seif MW, Jenkins H, Mould T, Woolas R, Murdoch JB, Dobbs S, Amso NN, Leeson S, Cruickshank D, Scott I, Fallowfield L, Widschwendter M, Reynolds K, McGuire A, Campbell S, Parmar M, Skates SJ, Jacobs I. Risk Algorithm Using Serial Biomarker Measurements Doubles the Number of Screen-Detected Cancers Compared With a Single-Threshold Rule in the United Kingdom Collaborative Trial of Ovarian Cancer Screening. J Clin Oncol 2015 Jun 20;33(18):2062-71. doi: 10.1200/JCO.2014.59.4945. Epub 2015 May 11.
  20. Sharma A, Burnell M, Gentry-Maharaj A, Campbell S, Amso NN, Seif MW, Fletcher G, Brunell C, Turner G, Rangar R, Ryan A, Jacobs I, Menon U. Quality assurance and its impact on ovarian visualization rates in the multicenter United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Ultrasound Obstet Gynecol. 2016 Feb;47(2):228-35. doi: 10.1002/uog.14929. PMID: 26095052; PMCID: PMC4755159.
  21. Barrett J, Jenkins V, Farewell V, Menon U, Jacobs I, Kilkerr J, Ryan A, Langridge C, Fallowfield L; UKCTOCS trialists. Psychological morbidity associated with ovarian cancer screening: results from more than 23,000 women in the randomised trial of ovarian cancer screening (UKCTOCS). BJOG: an international journal of obstetrics and gynaecology 2014 May 28;121(9):1071-9.
  22. Sharma A, Burnell M, Gentry-Maharaj A, Campbell S, Amso NN, Seif MW, Fletcher G, Brunel C, Turner G, Rangar R, Ryan A, Jacobs I, Menon U, United Kingdom Collaborative Trial of Ovarian Cancer S. Factors affecting visualization of postmenopausal ovaries: descriptive study from the multicenter United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology. 2013 Oct;42(4):472-7.
  23. Gentry-Maharaj A*, Sharma A*, Burnell M, Ryan A, Amso NN, Seif MW, Turner G, Brunell C, Fletcher G, Rangar R, Fallowfield L, Campbell S, Jacobs I, Menon U. Acceptance of transvaginal sonography by postmenopausal women participating in the United Kingdom Collaborative Trial of Ovarian Cancer Screening. Ultrasound Obstet Gynecol. 2013 Jan;41(1):73-9.
  24. Sharma A, Apostolidou S, Burnell M, Campbell S, Habib M, Gentry-Maharaj A, Campbell S, Amso N, Seif MW, Fletcher G, Singh N, Benjamin E, Brunell C, Turner G, Rangar R,Godfrey K, Oram D, Herod J, Williamson K, Jenkins H, Mould T, Woolas R,Murdoch J, Dobbs S, Leeson S, Cruickshank D, Fourkala E-O, Ryan A, Parmar M, Jacobs I*, Menon U*. Risk of epithelial ovarian cancer in asymptomatic women with ultrasound-detected ovarian masses: a prospective cohort study within the UK collaborative trial of ovarian cancer screening (UKCTOCS). Ultrasound Obstet Gynecol 2012;40(3):338-44.
  25. Sharma A, Gentry-Maharaj A, Burnell M, Fourkala EO, Campbell S, Amso N, Seif MW, Fletcher G, Brunel C, Turner G, Rangar R, Ford K, Ryan A, Jacobs I, Menon U for UKCTOCS. Assessing the malignant potential of ovarian inclusion cysts in postmenopausal women within the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a prospective cohort study. Bjog 2012;119(2):207-19.
  26. Burnell M, Gentry-Maharaj A, Ryan A, Apostolidou S, Habib M, Kalsi J, ,Skates S, Parmar M, Jacobs I, Menon U. Impact On Mortality And Cancer Incidence Rates Of Using Random Invitation From Population Registers For Recruitment To Trials. Trials, 2011. 12: p. 61.
  27. Fallowfield L, Fleissig A, Barrett J, Menon U, Jacobs I, Kilkerr J, Farewell V; UKCTOCS Trialists (Collaborators Jacobs I, Menon U, Campbell S, Fallowfield L, Skates SJ, Parmar M, McGuire A, Lopes A, Godfrey K, Oram D, Herod J, Williamson K, Seif M, Scott I, Jenkins H, Mould T, Woolas R, Murdoch J, Dobbs S, Amso NN, Leeson S, Cruickshank D, Luesley D, Cuzick J, Patnick J, Cheng KK, Bayne L, Law K, Finney K, Gentry-Maharaj A, Burnell M, Ryan A, Kalsi J, Davies S, Fletcher G, Apostolidou S, Liston R.) Awareness of ovarian cancer risk factors, beliefs and attitudes towards screening: baseline survey of 21,715 women participating in the UK Collaborative Trial of Ovarian Cancer Screening. Br J Cancer. 2010 Aug 10;103(4):454-61. doi: 10.1038/sj.bjc.6605809. Epub 2010 Jul 20.
  28. Menon U, Gentry-Maharaj A, Hallett R, Ryan A, Burnell M, Sharma A, Davies S, Philpott S, Lopes A, Godfrey K, Oram D, Herod J, Williamson K, Seif M, Scott I, Mould T, Woolas R, Murdoch J, Dobbs S, Amso N, Leeson S, Cruickshank D, McGuire A, Campbell S, Fallowfield L, Singh N, Dawnay A, Skates S, Parmar M, Jacobs I. Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). The lancet oncology, 2009. 10(4): p. 327-40.
  29. Menon U, Gentry-Maharaj A, Ryan A, Sharma A, Burnell M, Hallett R, Lewis S, Lopez A, Godfrey K, Oram D, Herod J, Williamson K, Seif M, Scott I, Mould T, Woolas R, Murdoch J, Dobbs S, Amso N, Leeson S, Cruickshank D, McGuire A, Campbell S, Fallowfield L, Skates S, Parmar M, Jacobs I. Recruitment to multicentre trials: lessons from UKCTOCS – Descriptive study BMJ, 2008. 337: p. a2079
  1. Jacobs IJ, Parmar M, Skates SJ, Menon U. Ovarian cancer screening: UKCTOCS trial - Authors' reply. Lancet. 2016 Jun 25;387(10038):2603-4. doi: 10.1016/S0140-6736(16)30849-2. PubMed PMID: 27353822.
  2. Menon U, Kalsi JK, Gentry-Maharaj A, Ryan A, Burnell M, Parmar M, Fallowfield L, Campbell S, McGuire A, Skates S, Jacobs I. Reply to P.F. Pinsky, C.P. Crum, and M.W. McIntosh et al. J Clin Oncol. 2016 Jan 10;34(2):201-2. doi: 10.1200/JCO.2015.64.1365. Epub 2015 Nov 16. PubMed PMID: 26573079.
  3. Sharma, A, Gentry-Maharaj A, Burnell M, Ryan A, Amso NN, Campbell S, Jacobs I, Menon U. "Reply: To Pmid 23456790."Ultrasound in obstetrics & gynecology: the official journal of the International Society of Ultrasound in Obstetrics and Gynecology May 2014; 43(5): 600-1.
  4. Gentry-Maharaj A, Kalsi J, Burnell M, Manchanda R, Menon U. Screening of symptomatic women for ovarian cancer. Lancet Oncol 2012;13(4):e138-9; author reply e39-40. (Letter to Editor)
  5. Menon U, Gentry-Maharaj A, Jacobs I. Ovarian cancer screening and mortality. JAMA 306(14):1544 (Letter to Editor)
  6. Jacobs I, Menon U. Can ovarian cancer screening save lives? The question remains unanswered. Obstet Gynecol 118(6):1209-1211, Dec 2011.
  7. Menon U. Ovarian cancer screening has no effect on disease-specific mortality. Evid Based Med. 2011 Sep 26.
  8. Menon U. Ovarian cancer: challenges of early detection. Nat Clin Pract Oncol. 2007 Sep;4(9):498-9.
  1. Webb AB, Berg CD, Castle PE, Crosby D, Etzioni R, Kessler LG, Menon U, Parmar M, Steele RJC, Sasieni PD. Considerations for using potential surrogate endpoints in cancer screening trials. Lancet Oncol. 2024 May;25(5):e183-e192. doi: 10.1016/S1470-2045(24)00015-9. PMID: 38697164.
  2. Dexter JM, Brubaker LW, Bitler BG, Goff BA, Menon U, Moore KN, Sundaram KM, Walsh CS, Guntupalli SR, Behbakht K. Ovarian cancer think tank: An overview of the current status of ovarian cancer screening and recommendations for future directions. Gynecol Oncol Rep. 2024 Mar 27;53:101376. doi: 10.1016/j.gore.2024.101376. PMID: 38590930; PMCID: PMC10999790.
  3. Sideris M, Menon U, Manchanda R. Screening and prevention of ovarian cancer. Med J Aust. 2024 Feb 14. doi: 10.5694/mja2.52227. Epub ahead of print. PMID: 38353066.
  4. Paramasivan S, Bhan A, Rodrigues R, Menon U. Trials Methodology Research: what is it and why should India invest in it? Lancet Reg Health Southeast Asia. 2024 Feb 2;22:100360. doi: 10.1016/j.lansea.2024.100360. PMID: 38482154; PMCID: PMC10934319.
  5. Nebgen DR, Domchek SM, Kotsopoulos J, de Hullu JA, Crosbie EJ, Paramanandam VS, Brood-van Zanten MMA, Norquist BM, Guise T, Rozenberg S, Kurian AW, Pederson HJ, Yuksel N, Michaelson-Cohen R, Bober SL, da Silva Filho AL, Johansen N, Guidozzi F, Evans DG, Menon U, Kingsberg SA, Powell CB, Grandi G, Marchetti C, Jacobson M, Brennan DJ, Hickey M. Care after premenopausal risk-reducing salpingo-oophorectomy in high-risk women: Scoping review and international consensus recommendations. BJOG. 2023 Nov;130(12):1437-1450. doi: 10.1111/1471-0528.17511. Epub 2023 May 2. PMID: 37132126.
  6. Virani S, Baiocchi G, Bowtell D, Cabasag CJ, Cho KR, Fortner RT, Fujiwara K, Kim JW, Köbel M, Kurtz JE, Levine DA, Menon U, Norquist BM, Pharoah PDP, Sood AK, Tworoger ST, Wentzensen N, Chanock SJ, Brennan P, Trabert B. Joint IARC/NCI International Cancer Seminar Series Report: expert consensus on future directions for ovarian carcinoma research. Carcinogenesis. 2021 Jun 21;42(6):785-793. doi: 10.1093/carcin/bgab043. PMID: 34037709; PMCID: PMC8427725.
  7. Nash Z, Menon U. Ovarian Cancer Screening: Current status and future directions. Best Practice & Research Clinical Obstetrics & Gynaecology 2020 Mar 3. DOI: 10.1016/j.bpobgyn.2020.02.010.  PMID:  32273169
  8. Menon U, Karpinskyj C, Gentry-Maharaj A. Ovarian Cancer Prevention and Screening. Obstet Gynecol. 2018 Apr 6. doi: 10.1097/AOG.0000000000002580. PubMed PMID: 29630008.
  9. Menon U.  Steps towards effective gynaecological cancer screening.  Nature Reviews Clinical Oncology 2018 May 31. DOI doi:10.1038/s41571-018-0049-4. PMID: 29855609.
  10. Dilley J, Gentry-Maharaj A, Menon U. Gynaecological surveillance in high risk women. Minerva Ginecol. 2016 Mar 1. [Epub ahead of print] PubMed PMID: 26930388.
  11. Gentry-Maharaj, A., Griffin, M., & Menon, U. (2018). Ovarian Cancer Prevention and Screening. In R. Eeles, C. Berg, & J. Tobias (Eds.), Cancer Prevention and Screening: Concepts, Principles and Controversies (pp 331-348). Wiley-Blackwell
  12. Gentry-Maharaj, A., & Menon, U. (2017). Development and identification of tumour markers. In D. Chi, A. Berchuck, D. S. Dizon, & C. M. Yashar (Eds.), Principles and Practice of Gynecologic Oncology (7th ed., pp.79-99). Wolters Kluwer.
  13. Gentry-Maharaj A, Kalsi J, Menon U. (Feb 2015) Screening for gynaecological cancers. In Pelvic Cancer Surgery: Modern Breakthroughs and Future Advances. Patel HRH, Mould T, Joseph JV and Delaney CP (Eds), chap 26, pp 267-282, Springer. ISBN 978-1-4471-4257-7
  14. Gentry-Maharaj A, Jacobs I, Menon U. (Dec 2014) Ovarian cancer-tumor markers and screening. In Berek & Hacker's Gynecologic Oncology, Sixth edition, Berek JS and Hacker NF (Eds), chap 10, pp 443-463, Lippincott Williams and Wilkins. ISBN 978-1-4511-9007-6
  15. Menon U, Griffin M, Gentry-Maharaj A. Ovarian cancer screening-current status, future directions. Gynecol Oncol. [Review]. 2014 Feb;132(2):490-5.
  16. Fourkala E-O, Gentry-Maharaj A, Menon U (2013). MUC16, alias CA125 and ovarian cancer. In: Mucins and Cancer. Taylor-Papadimitriou J, Burchell JM (Eds). Future Medicine, London, UK.
  17. Kalsi JK, Manchanda R, Menon U. Screening for gynecologic cancers. Expert Review of Obstetrics & Gynecology 2013;8(2):143-60.
  18. Gentry-Maharaj A, Jacobs I, Menon U. (2012) Development and identification of tumor serum markers. In Barakat, R.R., Berchuck, A., Markman, M., Randall,M.E. (eds). Principles and Practice of Gynecologic Oncology, 6th edition. Baltimore: Lippincott Williams & Wilkins.
  19. Gentry-Maharaj A, Menon U. Screening for ovarian cancer in the general population. Best Pract Res Clin Obstet Gynaecol2012;26(2):243-56.
  20. Jacobs I, Menon U. The sine qua non of discovering novel biomarkers for early detection of ovarian cancer: carefully selected preclinical samples. Cancer Prev Res (Phila) 2011 Mar; 4(3):299-302.
  21. Manchanda R, Jacobs IJ, Menon U. (2010) Tumour markers and screening. in Berek,j., Hacker,N (ed.) Practical Gynecologic Oncology. Philadelphia: Lippincott, Williams & Wilkin, 5th edition. 233-266.
  22. Hamilton W, Menon U. Ovarian cancer. BMJ. 2009 Nov 18;339:b4650. doi: 10.1136/bmj.b4650.
  23. Gentry-Maharaj A, Jacobs I, Menon U. (2009) Development and identification of tumor markers. in Principles and Practice of Gynecologic Oncology 5th edition (chapter 7), edited by William J Hoskins, Carlos A Perez, Robert C Young, Richard R Barakat, Maurie Markman
  24. Gentry-Maharaj A, Sharma A, Menon U. Ovarian Cancer. Review article in Geriatric Medicine, Vol 37, No 11, November 2007
  25. Sharma,A., Menon,U., Jacobs, IJ. (2007). Symptoms in the diagnosis of Ovarian Cancer. in Hillard,T. (ed.) The Yearbook of Obstetrics and Gynaecology, 159-170.
  26. Rosenthal,A., Menon,U., Jacobs,I.J. (2006). Ovarian Cancer Screening. in Reznick,R. (ed.) Contemporary Issues in Cancer Imaging: A Multidisciplinary Approach. Cambridge: Cambridge University Press.
  27. A Sharma, U Menon, I Jacobs. Symptoms in diagnosis of Ovarian Cancer. New Horizons in Obstetrics and Gynaecology (November 2007).
  28. Alexander Sefre,F., Menon,U., Jacobs,I.J. (2005). Ovarian cancer screening. in Farquharson,R. (ed.) Vignettes for the MRCOG. London: Quay Books, 57-62.
  29. Reynolds,K., Menon,U., Jacobs,I.J. (2005). Development and identification of tumour markers. in Hoskins,W.J., Perez,C.A., Young,R.C. (ed.) Principles and Practice of Gynecologic Oncology. 4th ed. Philadelphia: Lippincott Williams & Wilkins, 157-178.
  30. Menon,U., Jacobs,I.J. (2004). Tumour markers and Screening. in Berek,J., Hacker,N. (ed.) Practical Gynecologic Oncology. 4th ed. Philadelphia: Lippincott Williams & Wilkins, 43-66
  31. Menon,U., Brinkman,D.A., Skates,S.J., Jacobs,I.J. (2003). Screening: Ovarian Cancer. in Cuzick,J. (ed.) Evidence based oncology Part 3.
  32. Menon,U., Jacobs,I.J. (2002). CA125 and other tumour markers in screening and monitoring of ovarian cancer. in Altchek,A., Deligdisch,L. (ed.) Diagnosis and Management of Ovarian Disorders. New York: Academic Press.
  33. Menon,U., Jacobs,I.J. (2002). Screening for ovarian cancer. in Arulkumaran,S. (ed.) BailliŠre\'s Best Practice & Research Clinical Obstetrics & Gynaecology. London, 469-482.
  34. Menon,U., Jacobs,I.J. (2002). The current status of screening for ovarian cancer. in Jacobs,I.J., Shepherd,J.H., Oram,D.H., Blackett,A.D., Luesley,D., Berchuck,A., Hudson,C.N. (ed.) Ovarian Cancer. London: Oxford University Press, 171-178.
  35. Rufford B., Menon,U., and Jacobs IJ (2001). Ovarian Cancer Screening. Cancer Imaging 1(2), 14-16.
  36. Menon,U., Jacobs,I.J. (2000). Ovarian cancer screening in the general population. Ultrasound in Obstetrics and Gynaecology 350-353. ISSN: 0960-7692
  37. Menon,U., Jacobs,I.J. (2000). Tumour markers and Screening. in Berek,J., Hacker,N. (ed.) Practical Gynecologic Oncology. 3rd ed.. Philadelphia: Lippincott Williams & Wilkins, 39-58.
  38. Menon,U., Jacobs,I.J. (2000). Tumour markers. in Hoskins,W.J., Perez,C.A., Young,R.C. (ed.) Principles and Practice of Gynecologic Oncology. 3rd ed.. Philadelphia: Lippincott Williams & Wilkins, 165-181.
  39. Menon U, Jacobs IJ (1999) Ovarian cancer screening - a case study. Royal College of Obstetrics and Gynaecology. DIALOG - CD ROM.
  40. Menon U (1998) Screening and Diagnosis of Gynaecological Cancers. Minisymposium.Diplomat 5;184-8.